Eisai got an exclusive right to sell Gilead’s rheumatism drug in Japan


The American pharmaceutical company Gilead and the Japanese company Eisai have concluded a distribution and marketing agreement for the drug filgotinib for the treatment of rheumatism in Japan. Financial details were not provided.

Gilead is responsible for the production and market approval of filgotinib. Eisai is going to distribute the drug. Gilead is the cooperation partner of the biotechnologist Galapagos, listed on the stock exchange in Amsterdam. The two previously signed a deal about the development and marketing of filgotinib.

By: Peretz M.

Peretz M. is an accomplished economist and financial journalist with a deep understanding of the global economy and financial markets. He is a regular contributor to EconomicInform, where he provides expert analysis and commentary on current economic trends and events. With a strong educational background in economics, Peretz has a talent for breaking down complex economic concepts for a general audience and is able to provide insightful perspectives on a wide range of economic issues.

Add comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

By Leah Kunze

Recent Posts


About us

EconomicInform, EconomicInform.com is a product of EconomicInform LLC. We sincerely believe that economics is one of the most interesting and most underappreciated – in terms of getting some enjoyment out of reading the subject articles – sciences. More on that - at the link. Feel free to drop us a line.